William J. Crumb Jr., Ph.D.
Director Scientific Operations
Dr. William Crumb is a world-renowned expert in ion channel research with CRO experience since 1996, having founded Zenas Technologies, later to become NOVA Research Laboratories. Dr. Crumb has provided the hERG screening for the ILSI-HESI study which became foundation for the current S7B regulatory guidelines. In addition, Dr. Crumb has been contracted by the FDA since 2014 to provide manual ion channel screening in support of the CiPA initiative, the update to the S7B guidelines. His data is being used by the FDA to parameterize their in silico modeling as well as serving as a benchmark for automated patch clamp data. More recently, Dr. Crumb has developed the QT Fingerprinting methodology whereby clinical QTc changes can be predicted using preclinical ion channel data.
Dr. Crumb received his undergraduate degree from the University of New Orleans and his Ph.D in Pharmacology from Tulane University School of Medicine, New Orleans. He moved on to a postdoctoral research fellowship in the Department of Molecular Physiology and Biophysics at Baylor College of Medicine, Houston, TX. Dr. Crumb served as an Instructor for the Department of Pharmacology, the Director of Pediatric Clinical Research Unit and the Adjunct Assistant Professor, Department of Pediatrics, Division of Cardiology.
Dr. Crumb serves as a journal reviewer for the British Journal of Pharmacology, Molecular Pharmacology, Pediatric Research, American Journal of Physiology, Journal of Pharmacology and Experimental Therapeutics, and Cardiovascular Research.
Dr. Crumb is author in over 50 peer reviewed journal publications.
Benjamin J. Butterfield
Executive Director of Business Development
Benjamin has 19 years business development experience in the pharmaceutical industry. Benjamin served as business director for Chantest Inc. as well as the Toxikon Corporation. Benjamin served as Executive Director of Business Development, North American, for Cyprotex. Under this role Ben was involved in merger and acquisition activities including the acquisitions of Cellumen, Apredica and CeeTox Labs by Cyprotex, creating two new brick and mortar US based facilities. These efforts led to the sale of Cyprotex to Evotek in 2016.
Benjamin is trained in preclinical FDA compliance regulations GLP/GMP/ISO. Disease states studied: Pain Management, Neuropathic Pain, and Rheumatoid Arthritis, Neurological disorders, Migraines, Epilepsy, Diabetic Neuropathy, preclinical cardiovascular safety.